Myositis Antibodies and Interstitial Lung Disease.
Basuita M, Fidler LM.
J Appl Lab Med. 2022 Jan 5;7(1):240-258. doi: 10.1093/jalm/jfab108.
Diagnosis, pathogenesis and treatment of myositis: recent advances.
Carstens PO, Schmidt J.
Clin Exp Immunol. 2014 Mar;175(3):349-58. doi: 10.1111/cei.12194.
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.
JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598.
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ.
Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18.
Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.
Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, Senécal JL, Geny B, Landon-Cardinal O, Meyer A.
Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078. eCollection 2022.
Giant cell myositis and myocarditis revisited.
Oflazer P.
Acta Myol. 2020 Dec 1;39(4):302-306. doi: 10.36185/2532-1900-033. eCollection 2020 Dec.
Update on Myositis Therapy: From Today's Standards to Tomorrow's Possibilities.
Glaubitz S, Zeng R, Rakocevic G, Schmidt J.
Curr Pharm Des. 2022;28(11):863-880. doi: 10.2174/1381612827666211115165353.
Immune Checkpoint Inhibitor-induced Myositis.
Jayan A, Mammen AL, Suarez-Almazor ME.
Rheum Dis Clin North Am. 2024 May;50(2):281-290. doi: 10.1016/j.rdc.2024.02.003. Epub 2024 Mar 12.
Inclusion body myositis.
Warman-Chardon J, Breiner A, Bourque PR.
CMAJ. 2024 Apr 14;196(14):E486. doi: 10.1503/cmaj.231815.
Idiopathic inflammatory myositis.
Tieu J, Lundberg IE, Limaye V.
Best Pract Res Clin Rheumatol. 2016 Feb;30(1):149-68. doi: 10.1016/j.berh.2016.04.007. Epub 2016 May 26.
